Literature DB >> 8102072

Conformational and topographical considerations in the design of biologically active peptides.

V J Hruby1.   

Abstract

An outline of the basic considerations that are under development for the rational design of biologically active peptides and peptidomimetics is given. The necessary interplay of biophysical, chemical, and biological considerations is emphasized. The importance of properly designed biological assays to provide chemical information analogous to that from biophysical studies is discussed. The development of asymmetric synthesis in conjunction with conformational considerations for the preparation of specialized amino acids and amino acid mimetics is a critical aspect of the approach. The overall approach is illustrated with three examples from our laboratory: (1) the redesign of somatostatin to a highly potent and selective mu-opioid receptor antagonist using conformational and topographical considerations in design and for obtaining insights into the pharmacophor; (2) the use of topographical considerations for obtaining oxytocin antagonists; and (3) the application of designer amino acids prepared by asymmetric synthesis to obtain insight into the topographical requirements at delta-opioid receptors.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8102072     DOI: 10.1002/bip.360330709

Source DB:  PubMed          Journal:  Biopolymers        ISSN: 0006-3525            Impact factor:   2.505


  13 in total

Review 1.  A paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types: Emerging concepts and validation of combination immunotherapy.

Authors:  Pravin T P Kaumaya
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

2.  Structure-activity studies of peptides from the "hot-spot" region of human CD2 protein: development of peptides for immunomodulation.

Authors:  Jining Liu; Jinfa Ying; Vincent T K Chow; Victor J Hruby; Seetharama D Satyanarayanajois
Journal:  J Med Chem       Date:  2005-10-06       Impact factor: 7.446

Review 3.  Design of peptide and peptidomimetic ligands with novel pharmacological activity profiles.

Authors:  Victor J Hruby; Minying Cai
Journal:  Annu Rev Pharmacol Toxicol       Date:  2013       Impact factor: 13.820

4.  Comparison of cyclic delta-opioid peptides with non-peptide delta-agonist spiroindanyloxymorphone (SIOM) using the message-address concept: a molecular modeling study.

Authors:  P Gao
Journal:  J Comput Aided Mol Des       Date:  1996-08       Impact factor: 3.686

Review 5.  Ligand-based peptide design and combinatorial peptide libraries to target G protein-coupled receptors.

Authors:  Christian W Gruber; Markus Muttenthaler; Michael Freissmuth
Journal:  Curr Pharm Des       Date:  2010       Impact factor: 3.116

6.  Coupling constants again: experimental restraints in structure refinement.

Authors:  D F Mierke; T Huber; H Kessler
Journal:  J Comput Aided Mol Des       Date:  1994-02       Impact factor: 3.686

7.  Michael addition reactions between chiral equivalents of a nucleophilic glycine and (S)- or (R)-3-[(E)-enoyl]-4-phenyl-1,3-oxazolidin-2-ones as a general method for efficient preparation of beta-substituted pyroglutamic acids. Case of topographically controlled stereoselectivity.

Authors:  Vadim A Soloshonok; Chaozhong Cai; Takeshi Yamada; Hisanori Ueki; Yasufumi Ohfune; Victor J Hruby
Journal:  J Am Chem Soc       Date:  2005-11-02       Impact factor: 15.419

Review 8.  Peptide vaccines and targeting HER and VEGF proteins may offer a potentially new paradigm in cancer immunotherapy.

Authors:  Pravin T P Kaumaya; Kevin Chu Foy
Journal:  Future Oncol       Date:  2012-08       Impact factor: 3.404

Review 9.  Organic chemistry and biology: chemical biology through the eyes of collaboration.

Authors:  Victor J Hruby
Journal:  J Org Chem       Date:  2009-12-18       Impact factor: 4.354

10.  Peptide vaccines and peptidomimetics of EGFR (HER-1) ligand binding domain inhibit cancer cell growth in vitro and in vivo.

Authors:  Kevin Chu Foy; Ruthie M Wygle; Megan J Miller; Jay P Overholser; Tanios Bekaii-Saab; Pravin T P Kaumaya
Journal:  J Immunol       Date:  2013-05-22       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.